American Heart Journal
Volume 156, Issue 4 , Pages 623-632 , October 2008

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

  • Robert M. Califf, MD

      Affiliations

    • Duke Transitional Medicine Institute, Durham NC
    • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Robert M. Califf, MD, Duke Translational Medicine Institute, P.O. Box 17969, Durham, NC 27715.
    • ,
  • Mitradev Boolell, MD

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Steven M. Haffner, MD

      Affiliations

    • University of Texas Health Science Center, San Antonio, TX
    • ,
  • M. Angelyn Bethel, MD

      Affiliations

    • Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC
    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • John McMurray, MD

      Affiliations

    • Department of Medicine, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
    • ,
  • Anil Duggal, MD

      Affiliations

    • Novartis Pharma Corp, East Hanover, NJ
    • ,
  • Rury R. Holman, FRCP

      Affiliations

    • Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK
    • ,
  • for the NAVIGATOR Study Group

      Affiliations

    • See Appendix A for executive committee members. As chair of the trial, Dr Califf takes responsibility for the content of this article.

Received 12 May 2004 ,Accepted 20 May 2008.

References 

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21:518–524
  3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  4. McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J. 1999;138:S366–S375
  5. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  7. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–494
  8. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  9. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  10. Bethel MA, Holman R, Haffner SM, et al. Determining the most appropriate components for a composite clinical trial outcome. Am Heart J. 2008;156:633–640
  11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1999;22:S5–S19
  12. Alberti KGMM, Zimmet PG for the WHO Consultation. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999;
  13. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787–794
  14. Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocrine Rev. 1984;5:395–410
  15. Novartis Pharmaceutical Corp . Nateglinide prescribing information. Available at: http://www.starlix.com/starlix/medias/pdfs/us_starlix_pi.pdfLast accessed May 7, 2003
  16. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care. 2001;24:1221–1225
  17. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD). Circulation. 2003;107:1291–1296
  18. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting–enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  19. The Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2002;342:145–153
  20. The ALLHAT Investigators . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA. 2002;288:2981–2997
  21. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291–1296
  22. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. for the LIFE Study Group Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879–1886
  23. Hansson L, Lithell H on behalf of the SCOPE Study Investigators. The Study on COgnition and Prognosis in Elderly Hypertensives (SCOPE). In: Presented at the Joint 19th Scientific Meeting of the International Society of Hypertension and 12th European Meeting on Hypertension, Prague, Czech Republic, June 23-27. 2002;
  24. Yusuf S, Ostergren JB, Gerstein HC, et al. for the CHARM Investigators Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:48–53
  25. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  26. Bosch J, Yusuf S, Gerstein H, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–1562
  27. Paolisso G, Tagliamonte MR, Gambardella A, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens. 1997;11:307–312
  28. Top C, Cingozbay BY, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res. 2002;30:15–20
  29. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563–1574
  30. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  31. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14:1147–1151
  32. Novartis Pharmaceutical Corp . Diovan (valsartan) prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/diovan.pdfLast accessed May 7, 2003
  33. Cohn J, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  34. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31:353–360
  35. National Heart, Lung, and Blood Institute . ACCORD telebriefing prepared remarks. February 6, 2008. Available at: http://www.nhlbi.nih.gov/health/prof/heart/other/accord/index.htmLast accessed April 9, 2008
  36. Dormandy JA, Charbonnel B, Eckland DJ, et al. for the PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  37. Califf RM, DeMets DL. Lessons learned from recent cardiovascular clinical trials. Parts I and II. Circulation 2002;106:746-51 and 880-6.
  38. Balkau B, Shipley M, Jarret RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360–367
  39. Coutinho M, Wang Y, Gerstein HC, et al. The relationship between glucose and incident cardiovascular events. Diabetes Care. 1999;22:233–240
  40. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131–141
  41. DECODE Study Groupon behalf of the European Diabetes Epidemiology Study Group. Glucose tolerance and mortality: comparison of WHO criteria and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617–621
  42. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372
  43. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303
  44. Keech A, Simes RJ, Barter P, et al. for the FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  45. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA. 2003;289:2128–2130
  46. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  47. Cox DR, Snell EJ. The analysis of binary data. 2nd ed.. London: Chapman and Hall; 1989;
  48. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  49. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Disagreements between a central Clinical Events Committee and site investigator assessment of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Contr Trials Cardiovasc Med. 2001;2:1187–1194

 This study is funded by Novartis Pharma AG, Basel, Switzerland.

PII: S0002-8703(08)00389-X

doi: 10.1016/j.ahj.2008.05.017

American Heart Journal
Volume 156, Issue 4 , Pages 623-632 , October 2008

Article Tools

* Image Usage & Resolution